Trial Profile
A Randomized, Double-blind, Placebo-controlled 9-period Crossover, Dose-Escalation Study on the Safety, Bioavailability and Pharmacodynamics of Remimazolam Administered Intranasally as Powder and as Solution in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Sep 2020
Price :
$35
*
At a glance
- Drugs Remimazolam (Primary) ; Remimazolam
- Indications Anaesthesia; Sedation
- Focus Adverse reactions; Proof of concept
- Sponsors PAION
- 04 Sep 2020 Results published in the European Journal of Clinical Pharmacology.
- 04 Nov 2017 New trial record